$1.81
17.73% yesterday
NYSE, Jun 12, 10:20 pm CET
ISIN
US67080N1019
Symbol
NUVB
Sector
Industry

Nuvation Bio Inc - Ordinary Shares - Class A Stock price

$1.81
-0.34 15.81% 1M
-0.82 31.18% 6M
-0.85 31.95% YTD
-1.11 38.01% 1Y
-8.19 81.90% 5Y
-8.19 81.90% 10Y
-8.19 81.90% 20Y
NYSE, Closing price Thu, Jun 12 2025
-0.39 17.73%
ISIN
US67080N1019
Symbol
NUVB
Sector
Industry

Key metrics

Market capitalization $615.88m
Enterprise Value $159.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.59
P/S ratio (TTM) P/S ratio 56.19
P/B ratio (TTM) P/B ratio 1.47
Revenue (TTM) Revenue $10.96m
EBIT (operating result TTM) EBIT $-631.43m
Free Cash Flow (TTM) Free Cash Flow $-157.55m
Cash position $461.68m
EPS (TTM) EPS $-1.79
P/E forward negative
P/S forward 43.24
EV/Sales forward 11.23
Short interest 20.37%
Show more

Is Nuvation Bio Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Nuvation Bio Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Nuvation Bio Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11 11
-
100%
- Direct Costs 9.17 9.17
-
84%
1.79 1.79
-
16%
- Selling and Administrative Expenses 97 97
245% 245%
888%
- Research and Development Expense 111 111
70% 70%
1,012%
-631 -631
576% 576%
-5,753%
- Depreciation and Amortization 0.94 0.94
327% 327%
9%
EBIT (Operating Income) EBIT -631 -631
575% 575%
-5,761%
Net Profit -606 -606
780% 780%
-5,533%

In millions USD.

Don't miss a Thing! We will send you all news about Nuvation Bio Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Positive
Reuters
one day ago
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.
Neutral
Business Wire
one day ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZ...
Neutral
Business Wire
23 days ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), wil...
More Nuvation Bio Inc - Ordinary Shares - Class A News

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Head office United States
CEO David Hung
Employees 220
Founded 2018
Website www.nuvationbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today